Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.
Identifieur interne : 000545 ( PubMed/Corpus ); précédent : 000544; suivant : 000546Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.
Auteurs : Masato Yashiro ; Hirokazu Tsukahara ; Akihiro Matsukawa ; Mutsuko Yamada ; Yosuke Fujii ; Yoshiharu Nagaoka ; Mitsuru Tsuge ; Nobuko Yamashita ; Toshihiro Ito ; Masao Yamada ; Hiroshi Masutani ; Junji Yodoi ; Tsuneo MorishimaSource :
- Critical care medicine [ 1530-0293 ] ; 2013.
English descriptors
- KwdEn :
- Acute Lung Injury (drug therapy), Acute Lung Injury (immunology), Acute Lung Injury (pathology), Acute Lung Injury (virology), Animals, Antioxidants (pharmacology), Antioxidants (therapeutic use), Chemokine CXCL1 (drug effects), Chemokine CXCL1 (metabolism), Humans, Influenza A Virus, H1N1 Subtype, Influenza, Human (drug therapy), Male, Mice, Mice, Inbred C57BL, Neutrophil Infiltration (drug effects), Pneumonia, Viral (drug therapy), Prospective Studies, Recombinant Proteins (pharmacology), Recombinant Proteins (therapeutic use), Survival Analysis, Thioredoxins (pharmacology), Thioredoxins (therapeutic use), Tumor Necrosis Factor-alpha (drug effects), Tumor Necrosis Factor-alpha (metabolism), Viral Load (drug effects).
- MESH :
- chemical , drug effects : Chemokine CXCL1, Tumor Necrosis Factor-alpha.
- chemical , metabolism : Chemokine CXCL1, Tumor Necrosis Factor-alpha.
- chemical , pharmacology : Antioxidants, Recombinant Proteins, Thioredoxins.
- drug effects : Neutrophil Infiltration, Viral Load.
- drug therapy : Acute Lung Injury, Influenza, Human, Pneumonia, Viral.
- immunology : Acute Lung Injury.
- pathology : Acute Lung Injury.
- chemical , therapeutic use : Antioxidants, Recombinant Proteins, Thioredoxins.
- virology : Acute Lung Injury.
- Animals, Humans, Influenza A Virus, H1N1 Subtype, Male, Mice, Mice, Inbred C57BL, Prospective Studies, Survival Analysis.
Abstract
Influenza virus infections can cause severe acute lung injury leading to significant morbidity and mortality. Thioredoxin-1 is a redox-active defensive protein induced in response to stress conditions. Animal experiments have revealed that thioredoxin-1 has protective effects against various severe disorders. This study was undertaken to evaluate the protective effects of recombinant human thioredoxin-1 administration on influenza A virus (H1N1)-induced acute lung injury in mice.
DOI: 10.1097/CCM.0b013e3182676352
PubMed: 23222257
Links to Exploration step
pubmed:23222257Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.</title><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name></author><author><name sortKey="Nagaoka, Yoshiharu" sort="Nagaoka, Yoshiharu" uniqKey="Nagaoka Y" first="Yoshiharu" last="Nagaoka">Yoshiharu Nagaoka</name></author><author><name sortKey="Tsuge, Mitsuru" sort="Tsuge, Mitsuru" uniqKey="Tsuge M" first="Mitsuru" last="Tsuge">Mitsuru Tsuge</name></author><author><name sortKey="Yamashita, Nobuko" sort="Yamashita, Nobuko" uniqKey="Yamashita N" first="Nobuko" last="Yamashita">Nobuko Yamashita</name></author><author><name sortKey="Ito, Toshihiro" sort="Ito, Toshihiro" uniqKey="Ito T" first="Toshihiro" last="Ito">Toshihiro Ito</name></author><author><name sortKey="Yamada, Masao" sort="Yamada, Masao" uniqKey="Yamada M" first="Masao" last="Yamada">Masao Yamada</name></author><author><name sortKey="Masutani, Hiroshi" sort="Masutani, Hiroshi" uniqKey="Masutani H" first="Hiroshi" last="Masutani">Hiroshi Masutani</name></author><author><name sortKey="Yodoi, Junji" sort="Yodoi, Junji" uniqKey="Yodoi J" first="Junji" last="Yodoi">Junji Yodoi</name></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23222257</idno><idno type="pmid">23222257</idno><idno type="doi">10.1097/CCM.0b013e3182676352</idno><idno type="wicri:Area/PubMed/Corpus">000545</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000545</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.</title><author><name sortKey="Yashiro, Masato" sort="Yashiro, Masato" uniqKey="Yashiro M" first="Masato" last="Yashiro">Masato Yashiro</name><affiliation><nlm:affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Tsukahara, Hirokazu" sort="Tsukahara, Hirokazu" uniqKey="Tsukahara H" first="Hirokazu" last="Tsukahara">Hirokazu Tsukahara</name></author><author><name sortKey="Matsukawa, Akihiro" sort="Matsukawa, Akihiro" uniqKey="Matsukawa A" first="Akihiro" last="Matsukawa">Akihiro Matsukawa</name></author><author><name sortKey="Yamada, Mutsuko" sort="Yamada, Mutsuko" uniqKey="Yamada M" first="Mutsuko" last="Yamada">Mutsuko Yamada</name></author><author><name sortKey="Fujii, Yosuke" sort="Fujii, Yosuke" uniqKey="Fujii Y" first="Yosuke" last="Fujii">Yosuke Fujii</name></author><author><name sortKey="Nagaoka, Yoshiharu" sort="Nagaoka, Yoshiharu" uniqKey="Nagaoka Y" first="Yoshiharu" last="Nagaoka">Yoshiharu Nagaoka</name></author><author><name sortKey="Tsuge, Mitsuru" sort="Tsuge, Mitsuru" uniqKey="Tsuge M" first="Mitsuru" last="Tsuge">Mitsuru Tsuge</name></author><author><name sortKey="Yamashita, Nobuko" sort="Yamashita, Nobuko" uniqKey="Yamashita N" first="Nobuko" last="Yamashita">Nobuko Yamashita</name></author><author><name sortKey="Ito, Toshihiro" sort="Ito, Toshihiro" uniqKey="Ito T" first="Toshihiro" last="Ito">Toshihiro Ito</name></author><author><name sortKey="Yamada, Masao" sort="Yamada, Masao" uniqKey="Yamada M" first="Masao" last="Yamada">Masao Yamada</name></author><author><name sortKey="Masutani, Hiroshi" sort="Masutani, Hiroshi" uniqKey="Masutani H" first="Hiroshi" last="Masutani">Hiroshi Masutani</name></author><author><name sortKey="Yodoi, Junji" sort="Yodoi, Junji" uniqKey="Yodoi J" first="Junji" last="Yodoi">Junji Yodoi</name></author><author><name sortKey="Morishima, Tsuneo" sort="Morishima, Tsuneo" uniqKey="Morishima T" first="Tsuneo" last="Morishima">Tsuneo Morishima</name></author></analytic><series><title level="j">Critical care medicine</title><idno type="eISSN">1530-0293</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Lung Injury (drug therapy)</term><term>Acute Lung Injury (immunology)</term><term>Acute Lung Injury (pathology)</term><term>Acute Lung Injury (virology)</term><term>Animals</term><term>Antioxidants (pharmacology)</term><term>Antioxidants (therapeutic use)</term><term>Chemokine CXCL1 (drug effects)</term><term>Chemokine CXCL1 (metabolism)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza, Human (drug therapy)</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Neutrophil Infiltration (drug effects)</term><term>Pneumonia, Viral (drug therapy)</term><term>Prospective Studies</term><term>Recombinant Proteins (pharmacology)</term><term>Recombinant Proteins (therapeutic use)</term><term>Survival Analysis</term><term>Thioredoxins (pharmacology)</term><term>Thioredoxins (therapeutic use)</term><term>Tumor Necrosis Factor-alpha (drug effects)</term><term>Tumor Necrosis Factor-alpha (metabolism)</term><term>Viral Load (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Chemokine CXCL1</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Chemokine CXCL1</term><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antioxidants</term><term>Recombinant Proteins</term><term>Thioredoxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neutrophil Infiltration</term><term>Viral Load</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Acute Lung Injury</term><term>Influenza, Human</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Acute Lung Injury</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Acute Lung Injury</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antioxidants</term><term>Recombinant Proteins</term><term>Thioredoxins</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Acute Lung Injury</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype</term><term>Male</term><term>Mice</term><term>Mice, Inbred C57BL</term><term>Prospective Studies</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza virus infections can cause severe acute lung injury leading to significant morbidity and mortality. Thioredoxin-1 is a redox-active defensive protein induced in response to stress conditions. Animal experiments have revealed that thioredoxin-1 has protective effects against various severe disorders. This study was undertaken to evaluate the protective effects of recombinant human thioredoxin-1 administration on influenza A virus (H1N1)-induced acute lung injury in mice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23222257</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit. Care Med.</ISOAbbreviation></Journal><ArticleTitle>Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.</ArticleTitle><Pagination><MedlinePgn>171-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3182676352</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Influenza virus infections can cause severe acute lung injury leading to significant morbidity and mortality. Thioredoxin-1 is a redox-active defensive protein induced in response to stress conditions. Animal experiments have revealed that thioredoxin-1 has protective effects against various severe disorders. This study was undertaken to evaluate the protective effects of recombinant human thioredoxin-1 administration on influenza A virus (H1N1)-induced acute lung injury in mice.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective animal trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Research laboratory.</AbstractText><AbstractText Label="SUBJECTS" NlmCategory="METHODS">Nine-week-old male C57BL/6 mice inoculated with H1N1.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">The mice were divided into a vehicle-treated group and recombinant human thioredoxin-1-treated group. For survival rate analysis, the vehicle or recombinant human thioredoxin-1 was administered intraperitoneally every second day from day -1 to day 13. For lung lavage and pathological analyses, vehicle or recombinant human thioredoxin-1 was administered intraperitoneally on days -1, 1, and 3.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Lung lavage and pathological analyses were performed at 24, 72, and 120 hrs after inoculation. The recombinant human thioredoxin-1 treatment significantly improved the survival rate of H1N1-inoculated mice, although the treatment did not affect virus propagation in the lung. The treatment significantly attenuated the histological changes and neutrophil infiltration in the lung of H1N1-inoculated mice. The treatment significantly attenuated the production of tumor necrosis factor-α and chemokine (C-X-C motif) ligand 1 in the lung and oxidative stress enhancement, which were observed in H1N1-inoculated mice. H1N1 induced expressions of tumor necrosis factor-α and chemokine (C-X-C motif) ligand 1 in murine lung epithelial cells MLE-12, which were inhibited by the addition of recombinant human thioredoxin-1. The recombinant human thioredoxin-1 treatment started 30 mins after H1N1 inoculation also significantly improved the survival of the mice.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Exogenous administration of recombinant human thioredoxin-1 significantly improved the survival rate and attenuated lung histological changes in the murine model of influenza pneumonia. The protective mechanism of thioredoxin-1 might be explained by its potent antioxidative and anti-inflammatory actions. Consequently, recombinant human thioredoxin-1 might be a possible pharmacological strategy for severe influenza virus infection in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yashiro</LastName><ForeName>Masato</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsukahara</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Matsukawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Mutsuko</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Yosuke</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Nagaoka</LastName><ForeName>Yoshiharu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tsuge</LastName><ForeName>Mitsuru</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>Nobuko</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Masao</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Masutani</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yodoi</LastName><ForeName>Junji</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Morishima</LastName><ForeName>Tsuneo</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054360">Chemokine CXCL1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>52500-60-4</RegistryNumber><NameOfSubstance UI="D013879">Thioredoxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054360" MajorTopicYN="N">Chemokine CXCL1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020556" MajorTopicYN="N">Neutrophil Infiltration</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013879" MajorTopicYN="N">Thioredoxins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23222257</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3182676352</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000545 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000545 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23222257
|texte= Redox-active protein thioredoxin-1 administration ameliorates influenza A virus (H1N1)-induced acute lung injury in mice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23222257" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a StressCovidV1
| This area was generated with Dilib version V0.6.33. |  |